Casb7439 constructs
AssigneeGlaxosmithkline Biologicals SA
InventorsNormand Blais, Martin Harvey, Anthony Pilorget, Clement Rioux
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compounds and methods for increasing the recombinant production of CASB7439 polypeptides, and for methods of utilizing the same.
Claims20
(canceled)
A protein construct comprising a modified CASB7439 polypeptide selected from the group consisting of:
- (a) LVL055 (SEQ ID NO:1);
- (b) LVL111 (SEQ ID NO:3);
- (c) LVL137 (SEQ ID NO:5);
- (d) LVL141 (SEQ ID NO:7);
- (e) LVL144 (SEQ ID NO:9);
- and
- (f) LVL168 (SEQ ID NO:11).
(canceled)
11-13. (canceled)
A method of inducing an immune response to CASB7439 in a human or non-human animal comprising administering to the human or non-human animal an effective amount of a composition comprising an adjuvant and a protein comprising a polypeptide sequence selected from the group consisting of:
- (a) the polypeptide sequence set forth in SEQ ID NO:9;
- and
- (b) the polypeptide sequence set forth in SEQ ID NO:11.
A method of treating a human or non-human animal comprising the steps of:
- (a) selecting a human or non-human animal having cancerous cells that express CASB7439;
- and
- (b) administering to the human or non-human animal an effective amount of a composition comprising an adjuvant and a protein comprising a polypeptide selected from the group consisting of:
- (i) the construct set forth in SEQ ID NO:9;
- and
- (ii) the construct set forth in SEQ ID NO:11.
An immunogenic composition which comprises a protein comprising a polypeptide selected from the group consisting of:
- (a) the construct set forth in SEQ ID NO:9;
- and
- (b) the construct set forth in SEQ ID NO:11;
- and an adjuvant comprising 3DMPL, QS21 in a liposomal formulation, and CpG.
20-21. (canceled)
Dependencies are inferred from the claim text.